|
- 积分
- 13
- 威望
- 13
- 包包
- 49
|
Targeted therapies that deliver the expected anti-tumor
! F( S4 j* t) [! @+ p' Xeffects while mitigating the adverse effects are taking# w/ A4 t3 H9 P) I
the cancer world by storm. The need for such therapies
& O& P4 y- b# c3 G/ Din non-small cell lung cancer (NSCLC), where systemic3 j8 T G7 O7 C" Z5 w( N
cytotoxic chemotherapies still remain the backbone of
8 C8 L* t( l* ^% h( n5 hmanagement, is felt more than ever before. Runway! ?6 j, W6 i7 m7 P
success of immunotherapies such as Ipilimumab for2 H N+ [$ \4 k/ W: [9 B
melanoma has brought excitement among oncologists.0 ^* B9 I' a# ]
Immune-based treatments are in various stages of
3 Y1 Q- F- @! O! o9 K+ kevaluation for NSCLC as well. Immunotherapies using
# { W" N+ J' @( B8 X* S/ nstrategies of antigen based or cell based vaccines, and7 W [6 Q4 F! r' B5 y
blocking immune checkpoints are of substantial interest." ~- }% K8 R7 f; x
Meaningful clinical responses are yet to be reaped9 C4 P& q5 N, A
from these new treatment modalities.' V8 v& C7 q( Z9 R- L+ N% B
' V& s2 Y, a+ s3 C) C- k R- ^; v; s/ R
Lung cancer is the leading cause of cancerdeath: A5 B0 d0 ^1 k6 k3 ^$ ?9 V
worldwide. Majority of these patients have nonsmall1 ?5 k6 H9 t, F7 V% E
cell lung cancer (NSCLC). Traditional chemotherapy
$ ?+ |# A. ?* f/ W+ g4 x0 ~is limited by its high toxicity. Emerging data have
2 `) H0 n/ Q8 L2 E- r: k, [demonstrated promising outcome of immunotherapy in
* C8 p# J& X8 F% [, ZNSCLC. This review delineated the rationale and potential! K. m+ I; E; V) k( `
targets of cancer immunotherapy, with a summary) ~! r l) }( g& N) c& [' ~6 A
of immunotherapeutic agents for treatment of NSCLC./ O7 G# ], x5 X s( Y$ `# Y, f. w
Protein/peptide-based and cell-based vaccines, as well& h$ A) c, P( {0 K# F) ?
as immune checkpoint targeted agents such as Ipilimumab4 A9 _/ v. _- `3 t# l6 |
and PD-1 pathway inhibitors were discussed. In% g' A# d6 D& C) V4 t
addition, we reviewed ongoing immunotherapy-based
* H6 y' \1 g, m6 ?9 estudies including several major phase Ⅱ/Ⅲ clinical trials,; E' r- F' p& F* P6 m2 Z" A0 \
results of which will be available soon for incorporation
! k6 q O( p8 V, a* q7 |into clinical practice. |
|
发表于 2014-9-25 14:13
